Preparation of chitosan-Epigallocatechin-3-O-gallate nanoparticles and their inhibitory effect on the growth of breast cancer cells

Yingyi Liu,Peng Zou,Pei Qin,Siyi Hu,Liwei Liu,Jie Yue,Yueshu Feng,Yue Wang,Hui Wang,Yaotian Liang

doi:10.1142/s1793545818500189

Abstract

In this paper, we prepared the nanoparticle drug carrier system between nanoparticles — chitosan and Epigallocatechin-3-O-gallate (EGCG) for breast cancer cell inhibiting application. For this drug carrier system, chitosan acts as a carrier and EGCG as a drug. Which were systematically characterized and thoroughly evaluated in terms of their inhibition rate and biocompatibility. We also did a cell scratch test and the result indicated that the chitosan-EGCG nanoparticles have inhibitory effect on the growth of breast cancer cells. The inhibition rate could reach up to 21.91%. This work revealed that the modification of nanoparticles paved a way for specific biomedical applications.

Highlights

Nanoparticles are highlighted as potential drug carrier systems for cancer treatment for many years
In the last few years, EGCG has a certain degree of growth inhibition to the cancer cells, such as on HT-29 colon cancer cells, MCF-7 breast cancer cells, BGC823 gastric cancer cells, and HepG2 liver cancer cells.[10,11,12,13]
Low bioavailability and in vitro experimental results have been speculated that EGCG is preferentially excluded from the gallbladder into the colon, and has no e®ect on the blood.[14]

Summary

Introduction

Nanoparticles are highlighted as potential drug carrier systems for cancer treatment for many years. (-)-Epigallocatechin-3-O-gallate (EGCG) is a major ingredient from green tea, and possesses anticancer, anti-HIV, neuroprotective and DNA-protective properties.[8] EGCG is the most e®ective tea polyphenol which can mop up the reactive oxygen and has a kind of compound that possesses high antioxidant properties This compound can accomplish transformation, proliferation and inhibit tumor formation by preventing the in°ammatory process.[9] In the last few years, EGCG has a certain degree of growth inhibition to the cancer cells, such as on HT-29 colon cancer cells, MCF-7 breast cancer cells, BGC823 gastric cancer cells, and HepG2 liver cancer cells.[10,11,12,13] EGCG showed a strong inhibition towards free radical activity during the inhibition of cell proliferation.[9] Low bioavailability and in vitro experimental results have been speculated that EGCG is preferentially excluded from the gallbladder into the colon, and has no e®ect on the blood.[14] the multi hydroxyl molecular structure of EGCG has become a bottleneck in its application, such as poor lipid solubility, low bioavailability, unstable under physiological environment and slow absorption in vivo.[15] EGCG which belongs to polyphenols has good biological activity and is degraded under alkaline conditions. Dube et al found that in the 37C PBS (pH 7.4), when the initial concentration was 5 g/mL, the unencapsulated EGCG degraded by 50% after 10 min and completely within 40 min, degradation of 50% of encapsulated EGCG into nanospheres took 40 min and complete degradation occurred within 180 min.[16]

Methods

Results

Conclusion